Valuation: Exelixis, Inc.

Market Cap 13.99B 12.29B 11.43B 10.48B 19.7B 1,347B 20B 136B 53.01B 662B 52.51B 51.38B 2,290B P/E 2026 *
17.5x
P/E 2027 * 15x
Enterprise Value 13.17B 11.57B 10.76B 9.87B 18.55B 1,268B 18.83B 128B 49.9B 623B 49.43B 48.37B 2,156B EV / Sales 2026 *
5.07x
EV / Sales 2027 * 4.2x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 day-0.20%
1 week-0.68%
Current month+2.08%
1 month+5.05%
3 months+23.59%
6 months+27.36%
Current year+26.72%
1 week 54.2
Extreme 54.2
56.69
1 month 51.77
Extreme 51.77
57.57
Current year 39.71
Extreme 39.71
57.57
1 year 33.76
Extreme 33.755
57.57
3 years 18.64
Extreme 18.64
57.57
5 years 14.87
Extreme 14.87
57.57
10 years 8.58
Extreme 8.58
57.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Sell

Director

-9,812 0.0039%
6/1/26 Sell

Director

-3,925 0.0016%
5/27/26 Free

Director

8,367 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%-0.68%+24.00%+179.24% 13.99B
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+7.22%+64.67%+63.56% 56.67B
-2.15%-2.14%-21.86%-16.36% 23.28B
-0.77%-1.20%+3.38%+423.04% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%-0.63%+29.60%-32.53% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.41%+15.15%+426.20%+144.04% 12.22B
Average -0.96%+2.58%+80.84%+171.57% 25.42B
Weighted average by Cap. -0.81%+2.44%+61.80%+137.43%

Financials

2026 *2027 *
Net sales 2.6B 2.28B 2.12B 1.95B 3.66B 250B 3.71B 25.18B 9.84B 123B 9.75B 9.54B 425B 2.92B 2.57B 2.39B 2.19B 4.12B 282B 4.18B 28.37B 11.08B 138B 10.98B 10.74B 479B
Net income 812M 713M 663M 609M 1.14B 78.19B 1.16B 7.88B 3.08B 38.44B 3.05B 2.98B 133B 942M 828M 770M 706M 1.33B 90.73B 1.35B 9.14B 3.57B 44.61B 3.54B 3.46B 154B
Net Debt -819M -720M -669M -614M -1.15B -78.9B -1.17B -7.95B -3.1B -38.79B -3.08B -3.01B -134B -1.7B -1.49B -1.39B -1.27B -2.39B -163B -2.43B -16.46B -6.43B -80.32B -6.37B -6.23B -278B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-07-24 $55.41 -0.43% 816,308
26-07-23 $55.65 +1.22% 1,659,664
26-07-22 $54.98 -2.03% 1,656,466
26-07-21 $56.12 +1.06% 1,820,120
26-07-20 $55.53 -0.70% 2,381,658
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
55.65USD
Average target price
52.07USD
Spread / Average Target
-6.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EXEL Stock